Browsing Tag
Abbott Laboratories
11 posts
Is MiniMed (Nasdaq: MMED) worth watching after its IPO slide and before June earnings?
MiniMed (Nasdaq: MMED) is down from its IPO price. Read what June earnings, new product launches, and analyst targets could mean next.
Why Abbott Laboratories (NYSE: ABT) faces more than a legal bill after $70m Chicago baby formula ruling
Abbott was ordered to pay $70 million in a Chicago baby formula case. Read what the NEC verdict could mean for litigation risk, strategy, and ABT stock.
Abbott hit with $70m Illinois verdict in premature infant formula case
Illinois jury awards $70 million against Abbott in a premature infant NEC formula case. Read what the Cook County verdict means now.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition
Exact Sciences delivered record 2025 results ahead of its Abbott acquisition. Find out why cash flow, screening scale, and timing matter now.
Haemonetics (NYSE: HAE) acquires Vivasure Medical in €185m deal to expand vascular closure portfolio for structural heart procedures
Haemonetics acquires Vivasure Medical to expand its hospital closure portfolio with PerQseal Elite. Find out what this means for structural heart growth.
MiniMed IPO: Medtronic (NYSE: MDT) to separate diabetes business with Nasdaq filing under MMED
Medtronic files IPO for MiniMed, its diabetes business. Find out what the Nasdaq listing means for the company’s strategy, margins, and the diabetes tech sector.
Dangerous glucose monitor readings spark FDA Class I recall: What went wrong with Abbott sensors?
Abbott’s FreeStyle Libre 3 sensors linked to 7 deaths and 700+ injuries. Find out what the FDA warns and what patients should do now.
Abbott expands diagnostics empire with $23bn takeover of cancer-test leader Exact Sciences
Find out how Abbott’s $23B acquisition of Exact Sciences could reshape cancer diagnostics and redefine growth in oncology screening.
Biolinq’s needle-free glucose monitor wins FDA nod — Could this disrupt Dexcom and Abbott’s CGM dominance?
Biolinq Shine earns FDA de novo clearance as the first needle-free CGM, challenging Dexcom and Abbott in the diabetes tech market.